Shares in the microcap stock are up 85% for the year. And investors brave enough to go bargain hunting following the post COVID market rout to buy shares on 23 March will be sitting on gains of 270%.

By comparison the All Ordinaries Index (ASX: XAO) is up 49% since 23 March.

What does Dorsavi do?

Dorsavi provides wireless technology that's designed to accurately and objectively measure and analyse the way people move. How? Via tiny instruments that measure how you bend, twist and step. These include accelerometers, magnetometers and gyroscopes which combine with Dorsavi's patented algorithms.

The company offer 2 types of sensors. The first monitors movement while the second monitors muscle activity.

What did the AGM unveil to send Dorsavi's share price rocketing?

In his address to shareholders at today's virtual AGM, Dorsavi's Chairman Greg Tweedly revealed that the company had been highly resilient during the pandemic period, reducing costs as required and showing a level of growth in its recurring revenue.

On the cost front, Tweedly stated the company managed to reduce its cash expenses from $7.7 million in the 2019 financial year to $5.6 million in the 2020 financial year.

Dorsavi has also made progress on transitioning from consulting revenue to recurring revenue contracts. 74% of its FY2020 sales revenue was derived from recurring revenue. That's up from 51% in FY2019 and 25% in FY2018. Overall sales revenue, impacted by the pandemic, was down 20% year-on year, falling to $2.0 million from $2.5 million.

Additionally, Tweedly confirmed that Dorsavi has recently raised $2.15 million in capital at an issue price of 3.2 cents per share through a placement and entitlement offer. The company received $1.85 million from institutional and sophisticated investors via an oversubscribed placement and $300,000 from eligible shareholders via a 1-for-4 non-renounceable entitlement offer.

Among other allocations, the company plans to use the new capital to accelerate its product development, drive its commercialisation activities in the United States and invest in sales and marketing initiatives.

With the share price already up 85% in 2020, Dorsavi is one tiny ASX share that has seen big moves this year.

The post Why the Dorsavi (ASX:DVL) share price is flying 22% higher today appeared first on The Motley Fool Australia.

About Dorsavi

Dorsavi is a biotechnology company that develops innovative technologies that offer human body motion analysis for use in clinical applications, elite sports, and occupational health and safety.

Why the Dorsavi share price shoot higher?

Dorsavi announced yesterday that is has entered an agreement with QBE Australia to provide its wearable technology to QBE customers. The goal is to provide data insights that could help in reducing movement risk, injury claims and workers' compensation premiums. 

QBE will allocate $250,000 over 12 months to allow new and existing customers to access Dorsavi's equipment. QBE customers will be able to access both ViSafe and myVisafe technologies.

QBE Australia General Manager People Risk, Rob Kosova, stated; "safe work Australia estimates that workplace injury and disease costs around 4% of GDP." Additionally, he stated that over one third of these cases are due to body stressing or manual handling. The executive also stated that "partnering with Dorsavi is one way we can assist more customers prevent these injuries from happening."

The technology to be provided by Dorsavi will include on body sensors that will be used in real time and real work environments. These sensors will measure movement and muscle activity, quantify movement risk and guide decision making on risk mitigating strategies. 

CEO of Dorsavi, Dr Andrew Rochi, said;

"We are very excited to be working with QBE Australia to provide their customers with access to cutting edge technology and to profile risk more accurately. One of the goals for insurers is to be able to pro-actively manage risk and have remote visibility on where their potential risks are, allowing insurers and corporate groups to mitigate these risks and prove solutions before they are implemented. We look forward to adding value to the QBE Australia business and to their clients' businesses."

About the Dorsavi share price

Dorsavi released a business update and cash flow report in April for the March quarter. The company's cash balance was down to $1.92 million compared to $2.56 million at 31 December 2019. Net cash flow from operations was $870,000, however, the negative reduction in cashflow was 41% lower than the prior corresponding period. For the first 3 quarters of the 2020 financial year, recurring revenue was $1.16 million. This was a 22% increase on the prior corresponding period.

The business anticipated a challenging period as a result of the coronavirus with many clients of Dorsavi's technology requesting a pause in their subscriptions. All staff agreed to a pay cut of approximately 30% until the end of May 2020 and the company slashed operating expenses by 20% in order to optimise cash reserves.

The Dorsavi share price is up 512.5% from its 52 week low and is currently up 63.3% since the beginning of the year. The Dorsavi share price is down 2% since this time last year.

The post Why the Dorsavi share price rocketed 277% higher yesterday appeared first on The Motley Fool Australia.

Unfortunately not all shares are climbing higher with the market today. In fact, the four shares listed below have tumbled notably lower.

The Dorsavi Ltd (ASX: DVL) share price has tumbled 14% to 30 cents despite there being no news out of the company behind the ViSafe, ViMove and ViPerform motion analysis products. This latest decline means that DorsaVi's shares have now shed a disappointing 44% of their value year-to-date.

The Mayne Pharma Group Ltd (ASX: MYX) share price has continued to slide lower, this time by 5.5% to 76 cents. The pharmaceutical company's shares have come under heavy selling pressure in the last couple of days after it warned of tough trading conditions in the retail generic drugs channel. Although its shares look to be great value, I would suggest investors hold off an investment until conditions improve.

The Primary Opinion Ltd (ASX: POP) share price has fallen 11% to 2.4 cents a day after its shares rocketed a whopping 80% higher. Yesterday the shares of company which has a 48% interest in the Maggie Beer food products business rocketed higher after it announced that the former CEO of Bellamy's Australia Ltd (ASX: BAL), Laura McBain, would join the company this week as its new managing director.

The Resapp Health Ltd (ASX: RAP) share price has plunged a massive 78% to 7 cents after the digital healthcare company announced the failure of its Smartcough C study results. According to the release, analysis of the study data revealed many issues and the predefined endpoints for positive percent agreement and negative percent agreement with clinical diagnosis are unlikely to be met. Although it looks cheap now, I would caution against buying the dip.

The post Why these 4 ASX shares have tumbled lower today appeared first on The Motley Fool Australia.

In afternoon trade the motion analysis technology company's shares are up 8.5% to 38 cents.

What happened?

This morning the company announced that it has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its ViMove2 sensor designed to measure, record, and analyse movement and muscle activity of the lower back.

The FDA clearance is an important milestone for the company according to management, due largely to their belief that the product has a mass market clinical opportunity.

Combined with its patient app, ViMove2 allows both patients and therapists to monitor progress and improve adherence to treatment regimes. Ultimately, the company believes this will lead to better patient outcomes.

Shareholders will no doubt be very pleased to see the DorsaVi's share price continuing to head in the right direction. Around this time last month its shares sank to a 52-week low of 26 cents.

The post Dorsavi Ltd share price jumps 8% on FDA clearance appeared first on The Motley Fool Australia.

During trade today the motion analysis technology company's shares fell as much as 16% to a 52-week low of 26 cents.

Its shares have since rebounded, but are still down over 46% since the turn of the year. Not even a new contract win has been enough to shift sentiment.

Last week the company announced a three-year deal with Kieser Australia worth approximately $150,000.

The deal will see the recently launched ViMove 2 rolled out across Kieser's network of nine centres in Melbourne and Sydney.

ViMove is dorsaVi's wearable sensor technology used by medical and physiotherapy practices to assess and monitor movement.

The company also provides similar technology to the elite sports market and to the OHS market.

Companies using its OHS technology include BHP Billiton Limited (ASX: BHP) and Orora Ltd (ASX: ORA).

The post The Dorsavi Ltd share price just fell 16% to a 52-week low appeared first on The Motley Fool Australia.

Four shares which have performed far worse are listed below. Here's why they have sunk like stones today:

The Dorsavi Ltd (ASX: DVL) share price has fallen 9% to 38.5 cents following the release of its quarterly results. The update revealed a slowdown in sales growth during the third quarter of FY 2017. Sales grew just 4% during the quarter compared to the prior corresponding period, slowing its year-to-date sales growth to 23%.

The Santos Ltd (ASX: STO) share price has tumbled 6.5% to $3.41 after the government announced plans to crack down on high domestic gas prices. The government aims to reduce domestic prices by half, blocking the export of gas if necessary. Considering the company's high debt burden, I would stay clear of its shares despite today's drop.

The Somnomed Limited (ASX: SOM) share price has continued to slide lower, this time by almost 9% to $2.94. A disappointing quarterly update has been the catalyst for the sell-off in the sleep treatment company's shares. Weaker-than-expected sales in the United States led the company to downgrade its full-year earnings guidance.

The Ten Network Holdings Limited (ASX: TEN) share price has plunged 16% to 37.5 cents after the media company released its half-year report. The report revealed a 2.5% fall in revenue and a net loss of $232 million for the period. While a significant portion of the loss was a non-cash impairment charge, its performance is still extremely worrying in my opinion. I would suggest investors avoid Ten.

The post Why these 4 ASX shares have sunk like stones today appeared first on The Motley Fool Australia.

Dorsavi Ltd (ASX: DVL) has a market capitalisation of $66 million. It develops technology that accurately measures human movements in elite sports, occupational health and safety, and clinical settings.

Dorsavi's solutions include both sensors and software. The company earns both upfront product revenue and ongoing recurring fees. However, the breakdown of these two separate income streams is not currently disclosed.

The business has three key markets of Australia, Europe and the USA. Australia remains the largest revenue contributor at $1.1 million for the first half of 2017, but Europe and USA are far more significant in terms of growth potential. Indeed, the USA division recorded $0.5 million of revenue in the first half of 2017, exceeding total full-year 2016 revenue for the region.

For the first half of 2017, Dorsavi grew sales revenue by 33.8% to $1.7 million and reduced losses by 59% to $1.3 million. The company is well funded with $11.7 million in cash which given current growth rates, gross margins and cash burn should be sufficient to reach profitability in my opinion.

My one concern with Dorsavi is that wearable technology is a competitive field. I wouldn't be surprised to see the likes of Fitbit or even Apple become direct competitors to Dorsavi in the future.

Mach7 Technologies Ltd (ASX: M7T) has a market capitalisation of $54.9 million and develops healthcare imaging software. It also has a small medical 3D printing business.

The company's software is installed at 529 sites in 11 countries and customer contracts typically last five years with an increasing proportion of revenue paid monthly rather than upfront. It is costly for customers to switch providers and so combined with the transition to monthly invoicing, it is reasonable to view the revenue that Mach7 earns as recurring in nature.

In February, Mach7 announced that it expects to achieve profitability at the earnings before interest, tax, depreciation and amortisation (EBITDA) level in 2017 on the back of surging revenues. Revenue for the first half of 2017 rose 40% to $4.8 million on a pro forma basis. The company's growth potential is significant as its products address a multi-billion dollar global market.

As predominantly a software company, Mach7 earns very high gross margins – 94% for the first half of 2017. Consequently, most of the revenue growth for the period converted to incremental profits. EBITDA losses fell from $3.3 million in the prior corresponding period to $1.4 million for the first half of 2017.

Clearly, significant revenue growth is required in the second half of 2017 for Mach7 to achieve a breakeven result for the year and so there is a good chance that the company will fall short. Mach7 had $5.8 million in cash at 31 December 2016 so should not need to raise any further equity assuming this goal is met.

Unlike the above two businesses, Cyclopharm Limited (ASX: CYC) is already profitable and yet has the lowest market capitalisation of the three at $47.8 million. The company's main product is Technegas, a lung imaging technology whereby the patient inhales radioactive gas.

Cyclopharm also enjoys an attractive annuity like income stream. Technegas consists of a generator and consumable Patient Administration Sets (PAS). Generator sales are one-off, high value and low margin, whereas PAS sales are recurring, low value and high margin. As the base of installed generators grows, so too does Cyclopharm's high-margin PAS recurring revenue stream.

Technegas is currently approved for use in most developed global markets outside the US for testing Pulmonary emboli (PE). PE is where arteries in the lungs become blocked by a blood clot. Cyclopharm is currently pursuing regulatory approval in the US as well for Chronic Obstructive Pulmonary Disease (COPD) which is a much bigger market than PE.

Revenue rose 14% to $14.4 million in 2016 and underlying EBITDA from the Techegas business increased 15% to $3.4 million. However, statutory EBITDA was just $1.5 million largely because the company spent $1.1 million on progressing regulatory approvals.

And this is the risk with Cyclopharm. The company could potentially waste years of profits on pursuing FDA approval with no guarantee of success. On the other hand, if Technegas is approved for the US market or for COPD, then the stock would be worth multiples of its current price.

The post 3 speculative micro-cap shares that could make you a fortune appeared first on The Motley Fool Australia.

For those that aren't familiar with the company, dorsaVi serves the organisational health and safety, clinical, and elite sports markets with its patent protected technology.

This morning the company announced that it has signed a 12-month contract with Heathrow Airport which will see dorsaVi deliver a range of ViSafe services.

ViSafe is dorsaVi's health and safety wireless sensor technology that tracks and measures how people move in real-time work situations, allowing companies to assess risky movements.

In 2015 Heathrow Airport asked dorsaVi to assess the musculoskeletal impact of using manual handling aids for the transfer of airport baggage, versus the impact of transferring baggage without the use of aids.

The results of the study led to compliance with manual handling aids among baggage handlers increasing from 20% to 80%.

Heathrow Airport now plans to make a large terminal-wide investment in new manual handling aids. Two products have been shortlisted by the airport and ViSafe will be used to assist in the decision-making process.

The data will also be used to help optimise manual handling practices. After which it will be used in an interactive training application and an internal communications campaign in an effort to create behavioural change.

Finally, the company's recently launched myViSafe application will be used through the baggage handling area to monitor and promote safe workplace practice. Although the app only launched at the start of the month it is already attracting significant interest. Crown Resorts Ltd (ASX: CWN) is another company using it throughout its Melbourne and Perth businesses.

According to the release the project is estimated to be worth more than $100,000 to dorsaVi, with additional annuity revenue coming in via the myViSafe app.

Although it is often compared to Catapult Group International Ltd (ASX: CAT) due to its sports analytics segment, as far as I'm concerned the key driver of growth will be its health and safety segment.

One case study from a large organisation revealed that the introduction of ViSafe resulted in a drop from 72 injuries per quarter to just one. With work injuries estimated to cost businesses US$250 billion a year in the United States, I don't believe it is hard to see why the technology has enormous potential.

At this stage it would still be classed a high risk investment though. So for that reason I would restrict it to just a small part of your portfolio.

The post Why tech share Dorsavi Ltd surged higher today appeared first on The Motley Fool Australia.

Here's a quick recap:

• S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) up 1.2% to 5543 points
• ALL ORDINARIES (Index: ^AXAO) (ASX: XAO) up 1.1% to 5599 points
• AUD/USD at US 74.89 cents
• Iron Ore at US$82.25 a tonne, according to the Metal Bulletin
• Gold at US$1,177.03 an ounce
• Brent oil at US$53.00 a barrel

Rio Tinto Limited (ASX: RIO) helped propel the ASX 200 to a strong gain today. The miner's shares rose 3.1%, with BHP Billiton Limited (ASX: BHP) up 1.2%.

Meanwhile, Fortescue Metals Group Limited (ASX: FMG) announced it had become the lowest cost seaborne supplier of iron ore into China. Its shares rose 1.7%.

Australia and New Zealand Banking Group (ASX: ANZ) gained 2.5% as well. Westpac Banking Corp (ASX: WBC) climbed 2.1%.

Insurance business QBE Insurance Group Ltd (ASX: QBE) lifted 4.9%, while Insurance Australia Group Ltd (ASX: IAG) climbed 4.5%.

Ardent Leisure Group (ASX: AAD) was among the market's best today. It gained 4.2%. Independence Group NL (ASX: IGO) lifted 1.2% as well, and AMP Limited (ASX: AMP) rose 3.7%.

The aged care operators didn't fare so well. Estia Health Ltd (ASX: EHE) fell 3.3% and Regis Healthcare Ltd (ASX: REG) shed 0.7%.

Dorsavi Ltd (ASX: DVL) also fell 8.5%.

Here are Thursday's top stories:

1. Slater & Gordon Limited shareholders could face wipeout
2. 3 small cap growth stocks for a big 2017
3. 3 stocking fillers for smart investors this Christmas
4. Don't JUMP off this ASX dividend machine!
5. Iron ore price hits 2-year high: Will the bubble burst in 2017?
6. 4 shares to own in an Australian Recession
7. 5 small-cap shares I'm tipping to shine in 2017

The post ASX 200 soars: 13 shares you should have been watching appeared first on The Motley Fool Australia.

Unfortunately, however, not all companies have taken part in the rally. Here are five businesses that are sinking today…

Estia Health Ltd (ASX: EHE) shares rocketed higher on Tuesday, closing at a high of $2.82. However, they have now given up much of that gain with the shares once again trading at $2.65, down 4% for the day. Although the aged care operators rose as a result of a government announcement earlier in the week, investors may now realise that the respite for the industry may only be temporary. An investment in Estia Health isn't without its risks.

Regis Healthcare Ltd (ASX: REG), which also operates in the aged care sector, has fallen 2.3% as well – likely for the same reasons as Estia Health.

Northern Star Resources Ltd's (ASX: NST) share price has declined 1.5%, despite a slight uptick in the price of gold (to US$1,175 an ounce). Earlier this year, it seemed investors couldn't get enough of gold as the precious metal soared higher on global economic uncertainty. Although there is still plenty of uncertainty investors appear more confident that US interest rates will soon rise which has taken some of the shine out of gold – and the companies that produce it. The shares are now fetching $3.38, down 42.6% from their 52-week high less than six months ago.

Bega Cheese Ltd (ASX: BGA) shares have fallen another 1.7% to $4.55, extending their decline to 8.1% since last Friday. Indeed, that was the day that Bellamy's Australia Ltd (ASX: BAL) provided the market with a 'business update' in reporting a substantial slowdown in sales. Bega Cheese is also exposed to China, impacting investors' confidence levels in the business.

Dorsavi Ltd (ASX: DVL) shares have also tumbled 6.8% to 55 cents, although that isn't a result of any bad news. Indeed, the company's shares soared almost 16% on Wednesday after the company announced it had signed a new US sales agent for its workplace solution, ViSafe. In other words, today's decline is likely to be a case of profit taking, or else investors have simply had more time to process yesterday's news to give it a more appropriate valuation.

The post Why Dorsavi Ltd is one of 5 shares SINKING today appeared first on The Motley Fool Australia.

Companies such as Catapult Group International Ltd (ASX: CAT), Class Ltd (ASX: CL1), and Afterpay Holdings Ltd (ASX: AFY) have all put on incredible gains in excess of 75% for their respective shareholders.

Whilst I believe each of those companies could continue their impressive form in 2017, there are five more growth shares which I will keep a close eye on. They are as follows:

Bionomics Ltd (ASX: BNO)

Thanks to a strong pipeline of drugs and its partnership with US-giant Merck & Co, I believe this biopharmaceutical company has significant growth potential. One of its most promising drugs is targeting the anxiety treatment market estimated to be worth up to US$18.2 billion per year by 2020.

Dorsavi Ltd (ASX: DVL)

Often compared to Catapult, dorsaVi has patent protected technology that serves the organisational health and safety, clinical, and elite sports markets. Sales jumped a massive 122% in FY 2016 and I expect another strong performance in FY 2017. Especially after the technology won health and safety solution of the year award at the London Construction Awards in October.

Impedimed Limited (ASX: IPD)

Medical device company Impedimed has two key products which I believe have strong growth potential. Its SOZO device can be used by doctors, gyms, and health fanatics to scan the body and judge the user's overall health status. Then there's its L-Dex lymphoedema detection product which has launched in the US and is pursuing the Chronic Heart Failure market.

Nearmap Ltd (ASX: NEA)

This growing aerial imaging company may have upset investors with its capital raising last week, but there's no denying it has exciting growth potential in the U.S. market. If the funds raised are put to good use then we might just see growth accelerate in FY 2017.

PWR Holdings Ltd (ASX: PWH)

Brisbane-based PWR Holdings makes radiators and custom cooling systems for motorsports teams that race in the Formula One, NASCAR, and V8 Supercars. It's had a good start to FY 2017 and in the first quarter delivered strong organic growth. As the company earns the majority of its revenue from the United States and the UK, the predicted weakening of Australian dollar in 2017 will be a huge boost.

The post 5 explosive growth shares I will be watching in 2017 appeared first on The Motley Fool Australia.

Alternatively you could skip the coffee and buy a slice of one of these companies with massive growth potential instead.

a2 Milk Company Ltd (Australia) (ASX: A2M)

This dairy company has been growing at an explosive rate. Last week the company released its first quarter update which revealed a 40% increase in sales on the prior corresponding period. Strong sales growth in China and the UK, as well as an improvement in the United States helped drive the strong result. I believe the company is positioned for strong long-term growth that makes it a great investment today.

Bionomics Ltd (ASX: BNO)

Although this biopharmaceutical company has a strong pipeline of drugs which I believe could transform the company into a major player in the industry, there is one drug in particular which has caught my eye. Its BNC210 drug for the treatment of anxiety has produced positive phase II trials recently. Results show that the drug suppressed activation of the amygdala and outperformed the current standard of care, Ativan.

Dorsavi Ltd (ASX: DVL)

In FY 2016 dorsaVi reported a 122% jump in sales thanks to the growing popularity of its patent protected technology that serves the organisational health and safety, clinical, and elite sports markets. The award-winning technology tracks, measures, and assesses movement. Businesses use this to prevent work injuries, clinics use it to treat back pain, and sports teams like the Golden State Warriors use its technology to assess injury risk.

Nearmap Ltd (ASX: NEA)

Quick-growing photomapping software provider Nearmap is certainly one to watch thanks to its growth prospects in the United States. Although sales in the country still pale by comparison to its Australian sales, I have been impressed with its U.S. growth since introducing a paywall for its services. If the company can replicate its domestic success in the U.S. market, then investors will be rewarded handsomely.

Touchcorp Ltd (ASX: TCH)

Fintech company Touchcorp is a payment software solutions provider for a growing number of clients including Afterpay, 7-Eleven, and Optus. As well as having a strong domestic business, the company has been expanding overseas through deals with Cornèr Bank in Switzerland and Change Up in Scandinavia. Both of these deals are expected to provide Touchcorp with long-term transactional revenue streams. Half year revenue grew 20% and I expect an equally solid second half to the year.

The post 5 shares under $5 with massive growth potential appeared first on The Motley Fool Australia.

But is it time for them to move over?

Step-up tech company Dorsavi Ltd (ASX: DVL). I believe dorsaVi could have a very bright future ahead of it thanks to its patent protected technology that serves the organisational health and safety, clinical, and elite sports markets.

In FY 2016 dorsaVi reported a 122% jump in sales thanks to the growing popularity of its ViSafe, ViMove, and ViPerform products.

ViSafe is a wireless sensor technology that tracks and measures how people move in real-time work situations. This provides businesses with the ability to assess risky movements and then design fact-based solutions to create a safer work environment.

One case study from a large organisation revealed that its introduction resulted in a drop from 72 injuries per quarter to just one single injury. It's not hard to see why a growing number of companies use the technology – including the likes of BP, Newcrest Mining Limited (ASX: NCM), and Metcash Limited (ASX: MTS).

Especially when you learn that work injuries are estimated to cost businesses approximately US$250 billion a year in the United States.

Very promisingly, ViSafe won two awards at the London Construction Awards in October. It won the innovation of the year award for software, as well as the health and safety solution of the year award.

I believe this recognition should help the company build on a strong FY 2016. Sales of ViSafe rose 99% in FY 2016 to $1.7 million thanks to continued growth in the Australian market and significant expansion in both the UK and US markets.

The company's ViMove product is used by hundreds of clinics around the world to assess movement and muscle activity in the lower back in order to manage treatment options and guide to a safe recovery. A clinical trial has shown a 45% reduction in chronic lower back pain and a 73% improvement in function.

Finally, ViPerform tracks and measures how elite athletes move in real time. The wearable motion and muscle activity sensors record data at 200 frames per second, which its software then turns into easy-to-read and meaningful results.

This can be used to assess injury risk, identify running asymmetry, or even to optimise footwear. Currently the product is being used by sports teams such as the Golden State Warriors, the Brazilian national football team, and the mighty England cricket team.

Combined sales of ViMove and ViPerform increased 164% in FY 2016 thanks to growth in device sales and a strong increase in licensing revenue.

Overall I think dorsaVi has an extremely bright future ahead of it. But as exciting as the elite sports technology is, I believe it is the health and safety technology which will be the driver of growth over the next decade.

The expansion into the US market and the Construction Awards wins couldn't have come at better time with Donald Trump looking like he will embark on major infrastructure projects in the United States. This could see demand for ViSafe continue its meteoric rise.

As the company is not yet profitable there is a danger that another capital raising may be required further down the line. Currently the company has $5.8 million in the bank, which might just be enough to see them through the year. But it will be a close call.

For this reason investors may want to hold out until its half-year results in February to see how it is tracking. But until then, I would certainly keep a close eye on this exciting company.

The post Will Dorsavi Ltd be the next Catapult Group International Ltd? appeared first on The Motley Fool Australia.

The past month alone has seen the S&P/ASX 200 (Index: ^AXJO) (ASX: XJO) rally a staggering 8.7% which has pushed the index to a new seven-year high, with many quality stocks also pushing fresh 52-week highs.

It's a similar case overseas as well. European markets have been hitting fresh seven-year highs despite rumblings of troubles in Greece and the US market continues to go from strength-to-strength and flutters with record all-time highs.

That makes for slim pickings for investors who are more inclined to seek out opportunities amongst stocks selling at 52-week lows, where the potential to find a stock trading at a price which offers a significant discount to its value is more common.

This quote from well-known US investor Charles Brandes drives home the point:

"For long-term investors who evaluate share price in relation to business value, price declines can represent a tremendous opportunity in the form of discounts. Discounts are the building blocks of value."

Last week three stocks of interest hit new 52-week lows. While there is no guarantee that they don't have even further to fall, at the very least they could be worthy of a place on a value investor's watch list.

1. Reject Shop Ltd (ASX: TRS) touched a new low of $5.43 which means  the stock has declined by close to 50% over the last year. With research by Morningstar suggesting earnings per share (EPS) will touch a low this financial year (FY) before increasing in FY 2016 to 53.9 cents per share (cps), investors could currently buy this retailer on a forward price-to-earnings (PE) ratio of just 10.2x.
2. INGENIA STAPLED (ASX: INA) hit a new 52-week low of 39.5 cents and its share price has now lost 8.1% over the past year. The group remains well placed to consolidate the seniors living and lifestyle markets. Morningstar's data suggests the group will grow earnings over the next two years and in FY 2016 it should earn 4.2 cps. Based on this forecast the stock is trading on a forward PE of 9.4x.
3. Dorsavi Ltd's (ASX: DVL) share price has now fallen 20% over the past 12 months and touched a new low of 35 cents last week. The company continues to develop the commercialisation of its technology which provides wireless sensor movement monitoring. The company is yet to turn a profit but its potential remains exciting.

The post Are these the last 3 cheap stocks on the ASX? appeared first on The Motley Fool Australia.